Swedish Medical Products agency, the UK's Medical and Healthcare Products Regulatory Agency (MHRA) and the Italian government investigated finasteride and changed the label in their countries.

Excerpt from the page on the English Wikipedia's Finasteride http://en.wikipedia.org/wiki/Finasteride

There are case reports of persistent diminished libido or erectile dysfunction, even after stopping the drug.[18] In December 2008, the Swedish Medical Products agency concluded a safety investigation of finasteride and advised that finasteride may cause irreversible sexual dysfunction. The Agency's updated safety information lists difficulty in obtaining an erection that persists indefinitely, even after the discontinuation of finasteride, as a possible side effect of the drug.[19] The UK's Medical and Healthcare Products Regulatory Agency (MHRA) cites reports of erectile dysfunction that persists once use of finasteride has stopped.[20] Similar labeling changes have been made by the Italian government. For a period of time there was a discrepancy between European and North American warning labels regarding the risks of developing persistent sexual side effects from taking Propecia but after two years in April 2011 Merck revised the United States' warning in consumer and medical leaflets to include erectile dysfunction that may persist after stopping finasteride.[21] In April 2012, the FDA chose to approve Merck's proposed labeling from 2011 only after the warning label was further strengthened to include reports of persistent libido disorders, ejaculation disorders, orgasm disorders, and decreased libido. [22][23][24]